Physician profile
Tamra E Moss
NPI 1912340449
$1,740.74
in general payments reported to CMS, 2019-2025
25 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.03 · 2022: $196 · 2023: $522 · 2024: $636 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.85 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $258.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $190.21 | 2022-2025 | |
| Lilly USA, LLC | $118.52 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $108.06 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $86.89 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $75.50 | 2022-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $60.65 | 2022-2023 | |
| Axsome Therapeutics, INC. | $59.63 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $58.85 | 2022-2023 | Trintellix |
| Abbott Laboratories | $57.56 | 2023-2024 | Freestyle Libre 3 |
| Optinose US, INC. | $50.42 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.82 | 2022-2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $46.52 | 2024-2025 | Voquezna |
| Dexcom, INC. | $37.25 | 2022-2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.84 | 2024-2025 | Caplyta |
| Pfizer INC. | $26.95 | 2022-2023 | |
| Lundbeck LLC | $25.23 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $22.23 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $21.42 | 2025 | Fanapt |
| Regeneron Healthcare Solutions, INC. | $19.75 | 2024 | Evkeeza |
| Biohaven Pharmaceutical Holding Company LTD. | $17.86 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.79 | 2023 | Linzess |
| Biohaven Pharmaceuticals, INC. | $11.88 | 2021 | |
| Horizon Therapeutics Plc | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamra Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.